Stifel cuts Scotts Miracle-Gro stock rating after revenue guidance

Stifel downgraded Scotts Miracle-Gro (SMG) to Hold from Buy, citing concerns over U.S. consumer revenue guidance and potential channel inventory risk despite the company's reaffirmed full-year EBITDA guidance of $570-$590 million. The downgrade follows a recent 13.4% stock increase after the company's update, with analysts raising the price target to $71 from $70, reflecting confidence in the company's recovery phase. Despite a slight EPS beat in Q2 2025 at $3.98, revenue fell short at $1.42 billion, a 7% year-over-year decrease, and analysts express uncertainty regarding fiscal year 2026 margin expansion and earnings growth.

Analysis

Stifel has downgraded Scotts Miracle-Gro (SMG) stock from Buy to Hold, influenced by apprehension over the company's updated U.S. consumer revenue guidance, which analysts perceive as a potential signal of channel inventory risk. This concern, alongside uncertainties regarding fiscal year 2025's upside and a below-consensus outlook for fiscal year 2026 due to investment strategies and other financial elements, contributed to the revised rating. Despite the downgrade, Stifel increased its price target for SMG to $71 from $70, acknowledging the company's recovery progress and its current valuation at 17 times projected fiscal year 2026 earnings per share, aligning it with Consumer Staples Peers. This follows a notable 13.4% surge in SMG's share price after a company update where key guidance points were reaffirmed. However, Scotts Miracle-Gro's second-quarter 2025 financial results were mixed: earnings per share came in at $3.98, slightly above the $3.94 forecast, but revenue was $1.42 billion, falling short of the anticipated $1.5 billion and representing a 7% year-over-year decline in total net sales. The company reiterated its full-year EBITDA guidance of $570 million to $590 million and maintained its fiscal year 2025 forecast for low single-digit U.S. Consumer net sales growth and a non-GAAP adjusted gross margin of approximately 30%. Supporting a more positive view, consumer point-of-sale sales increased by 12% through the first half of the fiscal year, and the company anticipates a $30 million year-over-year reduction in interest expense. InvestingPro data suggests the stock is trading slightly above its Fair Value, characterized by a high P/E ratio of 106x and an EV/EBITDA multiple of 13.9x. Analyst opinions on SMG diverge: Truist Securities raised its price target to $75, maintaining a Buy rating, whereas UBS holds a Neutral stance with a $54 price target, citing the need for greater clarity on margin expansion and earnings growth for fiscal year 2026. Stifel analysts characterize SMG shares as likely to remain volatile and conclude that the current risk-reward balance justifies a neutral position, especially considering peak earnings growth amid the ongoing recovery, while still recognizing the U.S. Consumer business as a robust platform for future growth and the company's consistent dividend payments for 21 years, currently yielding 4%.

Key Decisions for Investors

• Investors should diligently monitor Scotts Miracle-Gro's U.S. consumer revenue performance and channel inventory levels, as these factors are highlighted as key risks that could impact fiscal year 2025 results and beyond.
• Given the stock's recent 13.4% appreciation and high P/E ratio of 106x, alongside Stifel's assessment of peak earnings growth during its recovery phase, a careful evaluation of the risk-reward profile is advised, balancing reaffirmed guidance against potential fiscal year 2026 uncertainties.
• The spread in analyst price targets (Stifel Hold at $71, Truist Buy at $75, UBS Neutral at $54) underscores the mixed outlook; therefore, investors should critically assess the company's strategy for achieving sustained margin expansion and earnings growth, particularly for fiscal year 2026.
• While the consistent dividend history (21 consecutive years, current 4% yield) and focus on the U.S. Consumer business may appeal to income-oriented and long-term investors, these positives should be weighed against the stock's noted volatility and the prevailing concerns over its future growth trajectory and valuation.